2-Hydroxy-3,4-Dimethoxybenzoic Acid

2-Hydroxy-3,4-Dimethoxybenzoic Acid

SCHEMBL419244

COc1ccc(C(=O)O)c(O)c1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
TDP1 Q9NUW8 2/20 1.00
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPK1 P28482 2/20 0.49
HSD17B10 Q99714 2/20 0.49
ALOX15 P16050 1/20 0.49
HPGD P15428 3/20 0.47
CDC25B P30305 1/20 0.46
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA4 P22748 2/20 0.46
CA6 P23280 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
CA3 P07451 1/20 0.46
PKM P14618 1/20 0.46
CA5A P35218 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Hydroxy-3,4-Dimethoxybenzoic Acid SCHEMBL28127138 0.98 MAPT (0.96) MAPTTDP1KDM4EALDH1A1MAPK1
SCHEMBL27713896 0.86 MAPT (0.76) MAPTTDP1KDM4EALDH1A1MAPK1
SCHEMBL11026756 0.85 MAPT (0.73) MAPTTDP1KDM4EALDH1A1MAPK1
SCHEMBL335038 0.85 MAPT (0.73) MAPTTDP1KDM4EALDH1A1MAPK1
SCHEMBL29405531 0.85 MAPT (0.73) MAPTTDP1KDM4EALDH1A1MAPK1
SCHEMBL29378830 0.84 MAPT (0.72) MAPTTDP1KDM4EALDH1A1MAPK1
SCHEMBL3189109 0.84 MAPT (0.72) MAPTTDP1KDM4EALDH1A1MAPK1
SCHEMBL102827 0.84 MAPT (0.72) MAPTTDP1KDM4EALDH1A1HPGD
SCHEMBL1434290 0.83 MAPT (0.71) MAPTTDP1KDM4EALDH1A1MAPK1
Hydrochloric Acid SCHEMBL5061862 0.82 MAPT (0.70) MAPTTDP1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119529253-A Preparation method and application of citronellol diol related polyester 武汉科技大学 2025-02-28 CN claimed
US-11198830-B2 Grease composition SHELL OIL COMPANY (US) 2021-12-14 US claimed
CN-104345550-A Colored photosensitive resin composition, color filter, and liquid crystal display device having the same DONGWOO FINE CHEM CO LTD 2015-02-11 CN claimed
EP-2448913-B1 CONTINUOUS METHOD FOR ACYLATING AMINO GROUP-CARRYING ORGANIC ACIDS CLARIANT FINANCE BVI LTD (VG) 2013-04-24 EP claimed
EP-2448904-B1 CONTINUOUS METHOD FOR PRODUCING ESTERS OF AROMATIC CARBOXYLIC ACIDS CLARIANT FINANCE BVI LTD (VG) 2013-04-17 EP claimed
US-20120157370-A1 WASHING PERFORMANCE USING RADICAL TRAPS HENKEL AG & CO. KGAA (DE) 2012-06-21 US claimed
EP-2448904-A2 CONTINUOUS METHOD FOR PRODUCING ESTERS OF AROMATIC CARBOXYLIC ACIDS Clariant Finance (BVI) Limited (VG) 2012-05-09 EP claimed
EP-2448913-A2 CONTINUOUS METHOD FOR ACYLATING AMINO GROUP-CARRYING ORGANIC ACIDS Clariant Finance (BVI) Limited (VG) 2012-05-09 EP claimed
US-20120090983-A1 Continuous Method For Acylating Amino Group-Carrying Organic Acids CLARIANT FINANCE (BVI) LIMITED (VG) 2012-04-19 US claimed
US-20120088918-A1 Continuous Method For Producing Esters Of Aromatic Carboxylic Acids CLARIANT FINANCE (BVI) LIMITED (VG) 2012-04-12 US claimed
WO-2011000464-A2 CONTINUOUS METHOD FOR PRODUCING ESTERS OF AROMATIC CARBOXYLIC ACIDS CLARIANT INTERNATIONAL LTD (CH) 2011-01-06 WO claimed
WO-2011000461-A2 CONTINUOUS METHOD FOR ACYLATING AMINO GROUP-CARRYING ORGANIC ACIDS CLARIANT INTERNATIONAL LTD (CH) 2011-01-06 WO claimed
WO-2026106929-A1 DIHYDROQUINAZOLINES USEFUL AS CYTOMEGALOVIRUS ANTIVIRAL AGENTS ASSEMBLY BIOSCIENCES, INC. (US) 2026-05-21 WO disclosed
EP-4680706-A1 BIODEGRADABLE GREASE COMPOSITION Shell Internationale Research Maatschappij B.V. (NL) 2026-01-21 EP disclosed
WO-2025217420-A1 PYRIDINONE COMPOUNDS, METHODS AND USES THEREOF ZENO MANAGEMENT, INC. (US) 2025-10-16 WO disclosed
EP-4626554-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF Tiger Biotherapeutics Inc. (US) 2025-10-08 EP disclosed
EP-0887344-B1 Quinolines and quinazolines useful in therapy PFIZER LTD (GB) 2003-12-03 EP disclosed
US-6417194-B1 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PFIZER, INC. 2002-07-09 US disclosed
US-6048864-A Quinolines and quinazolines useful in therapy PFIZER INC (US) 2000-04-11 US disclosed
EP-0887344-A1 Quinolines and quinazolines useful in therapy Pfizer Limited (GB) 1998-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157370-A1 WASHING PERFORMANCE USING RADICAL TRAPS MPO, DNASE1, PLD4 MAPT 2017/4885TDP1 201/4885KDM4E 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.